To discern the mechanism(s) that underlie abnormal cholesteryl ester transfer (CET) in patients with hypercholesterolemia, we have studied this dysfunctional step in reverse cholesterol transport in 13 subjects with genetically heterogeneous forms of hypercholesterolemia (HC). In all HC patients, the mass of CE transferred in whole plasma from HDL to VLDL and LDL increased rapidly initially and was significantly greater than in controls at 1, 2, and 4 h (P < 0.005).
key step in reverse cholesterol transport, but also because it provides a pathway for the redistribution, reutilization, as well as the eventual excretion of cholesteryl esters generated in plasma on HDL by the lecithin-cholesterol acyltransferase (LCAT)' reaction. Disturbances in cholesterol ester transfer (CET) could have atherogenic consequences. If, for example, CET were inhibited and, as a result, the movement of cholesterol from tissues to HDL were retarded, it might predispose to the accumulation of cholesterol in arterial tissues. On the other hand, if CET were increased, and the acceptor apo B-containing lipoproteins became abnormally enriched in CE, the physical properties and metabolism ofthese particles may be altered.
We recently have observed that patients with genetically heterogeneous forms of hypercholesterolemia have disturbances in lipoprotein composition which may facilitate CET (3) . Specifically, we have found that their VLDL is enriched in free cholesterol and this abnormality has been reported by Morton to promote CE accumulation in VLDL (4) . Moreover, our observation that the core lipid content of VLDL was enriched in CE compared with triglyceride (TG) implied that CET was increased in vivo. To determine whether CET was in fact accelerated as our compositional studies suggested, we have studied CET in a group of hypercholesterolemic patients.
Methods
Human subjects. 13 subjects (5 male; 8 female) with hypercholesterolemia and normal fasting triglyceride levels (Cholesterol, 304±30 mg/ dl; TG, 128±43 mg/dl; HDL-cholesterol (C), 54±11 mg/dl; mean±SD) were studied (mean age, 44.1±11.6 yr; mean±SD; range 21-50 yr). All participants had fasting cholesterol levels in the untreated state measured on two or more occasions that were greater than two standard deviations ofthe mean defined by Lipid Research Clinics standards (5) for their age and sex. Two female patients had heterozygous familial hypercholesterolemia; 9 had familial combined hyperlipidemia based on a positive family history ofhyperlipidemia and premature cardiovascular disease; and two had polygenic forms of hypercholesterolemia.
The apo E phenotypes of 11 of 13 of these subjects were: 6 had E3/E3 and 5 had ESE3 apoE isoforms. No effort was made to characterize the molecular basis for cholesterol elevation in any patient. Informed consent was obtained. All patients had followed American Heart Association Phase I diets for at least 4 mo before the study. None had renal disease, none were vegetarians, cigarette smokers, athletes, none took drugs known to affect lipid metabolism, or had diabetes. The normolipidemic control subjects (Cholesterol, 163±22 mg/dl; TG, 107±38 mg/dl; HDL-C, 55±9 mg/dl; mean±SD) were taking no medications and were matched for sex, approximate age, weight, level of physical activity, and smoking habits. Venous blood samples were collected after an overnight fast in Na EDTA-containing tubes and plasma was separated promptly by low speed centrifugation. Enzymatic kit procedures were employed to later quantitate cholesterol (BoehringerMannheim Inc., Indianapolis IN) and triglyceride (Sigma Chemical Co., St. Louis, MO) in an aliquot ofplasma which was frozen at -200C, and from this same aliquot HDL-C also was measured by a standardized Lipid Research Clinic procedure (6) . Free cholesterol was estimated with the same components of the cholesterol kit except that CE hydrolase was omitted. Cholesteryl ester was calculated from the difference between total and free cholesterol. For lecithin determination, 0.3-ml aliquots of VLDL, LDL, and HDL were removed, mixed with 0.1 ml of 0.15 M NaCl-lmM EDTA solution, and extracted by the Bligh and Dyer procedure (7) . All lipid extracts were spotted on activated silica gel (E. Merck, Darmstadt, FRG) thin layer plates (0.5 mm thickness), and lecithin separated from the other major phospholipids using a solvent system of chloroform/methanol/acetic acid/water, 25:15:4:2 by volume. The lecithin spots were scraped into glass tubes and the lipid phosphorus determined by the modified Bartlett's procedure (8) .
Cholesteryl ester transfer in incubatedplasma. The mass transfer of cholesteryl ester from HDL to apo B-containing lipoproteins was measured during incubation at 370C in a metabolic shaker in the presence of 1.5 mM dithio-bis-dinitrobenzoic acid (DTNB) to inhibit plasma LCAT as previously described (9) . Aliquots of plasma were removed before and at 1, 2, 4, and 6 h, chilled on ice, and VLDL + LDL were precipitated with 0.1 vol of heparin/MnCl2 to give final concentrations of MnCl2 (0.092 M) and heparin (1.3 mg/ml) (10). MnCl2 at this concentration has been found to not precipitate a significant quantity of apo E-containing HDL (1 1). At each sampling interval, the mass of free and total cholesterol present in the supernatant were measured and the amount of CE transferred into the apo B-containing lipoproteins was calculated from the difference between the two values. The mass ofCE transferred at each time interval was determined by subtracting this value from zero-time CE in HDL. Cholesteryl ester transfer protein (CETP) mass was measured in I1 of 12 subjects by radioimmunoassay in the laboratory of Dr. Yves Marcel at the Clinical Research Institute of Montreal (12) .
Lipoprotein fractionation. In the series of recombination experiments performed, plasma was obtained from 6 of the 13 hypercholesterolemic patients (3 male, 3 female) and 6 normolipidemic control subjects of the same sex and spun at a density of 1.063 to separate the VLDL and LDL (top) and HDL + VHDL (bottom) fractions. When it was apparent that the accelerated CET observed in the intact plasma of hypercholesterolemic subjects was associated with their top fraction, VLDL (< 1.006 g/ml) and LDL (1.006-1.063 g/ml) from the same subjects were isolated from plasma by sequential preparative ultracen- patients, VLDL subfractions (VLDLI, VLDL2, and VLDL3) were isolated from plasma sequentially by a nonlinear salt gradient procedure described by Lindgren (13) . Polyacrylamide gel electrophoresis ofthe VLDL subfractions from two hypercholesterolemic and two control subjects was performed with analytical IEF of gels prepared in 8 M urea with pH 4-6.5 ampholines (LKB, Sweden) as described by Cabana et al. ( 14) to identify isoforms of apolipoproteins E, CII, and CIII. Student's t test was used to determine the significance of the differences of the mean values observed in CET and lipoprotein composition in the control and hypercholesterolemic groups.
Results
Cholesteryl ester transfer. The CET responses ofthe hypercholesterolemic (HC) patients and controls differed markedly ( Fig.   1 ) during the 6-h incubation ofwhole plasma. In contrast to the initial delay and slow curvilinear increase in CET observed in controls, the HC group demonstrated a rapid initial increment and an overall hyperbolic response to levels that were significantly greater than those ofcontrols at 1, 2 (P < 0.001), and 4 h (P < 0.005). To assure that the differences observed in CET between HC and control subjects were not attributable to variations in the extent to which LCAT was inhibited, LCAT (Table II) . The mass of all lipids tended to be higher in HC VLDL than in controls. The TG/CE ratio was lower (P < 0.1) and the free cholesterol (FG)/lecithin ratio significantly higher (P < 0.025) in the HC VLDL than in controls. (Table II) . In HC LDL, all lipids were significantly increased reflecting the increase in LDL mass. The TG/CE and FC/lecithin ratios of HC LDL, however, both were significantly lower than those of the controls. HDL lipids were similar in the two groups, but the TG/ CE ratio tended to be higher in HC HDL than in controls. All three control VLDL subfractions (Table III) contained less lipid (total, free and esterified cholesterol, and triglyceride) than the corresponding HC subfractions. The major differences in these constituents were in VLDL1. Here the TG/CE ratio was significantly reduced (P < 0.001) and the FC/lecithin ratio increased (P < 0.05), indicating that its core was enriched in CE and its surface in FC; these ratios were very similar in HC and control VLDL2 and VLDL3. Analysis by PAGE with isoelectric focusing revealed no quantitative differences in the isoforms of apoproteins E, CII, and CIII in the VLDL subfractions.
Discussion
During the metabolism oflipoproteins in plasma, three parallel systems normally function to modify both their core and surface lipid composition. These include: (a) LCAT, which generates CE on HDL from free cholesterol acquired from other lipoproteins, the blood elements, and peripheral tissues (15) homoexchange of CE between HDL and LDL is also acceler-
ated. HFkrs
The reasons for our finding that VLDL rather than CETP drives CET abnormally, as described in these other reports, may relate in part to marked differences in assay conditions; foremost among these is the fact that VLDL function in CET was not examined. The isotopic method employed by Groener et al. to study hyperlipidemic patients earlier (19) for example, involved the 16-h incubation of delipidated HC plasma with a standard mixture of radiolabeled HDL CE and LDL from a control pool; in these studies LDL rather than VLDL, which is VL.DL3 normally the predominant CE acceptor, was used as an accep-VLDL3 tor lipoprotein particle. In this study, we have measured the mass of CE transferred from each subjects' own HDL to their VLDL + LDL either in intact plasma or in a system containing _-_ freshly isolated lipoproteins from the same HC and control subjects. poproteins, the acceptor of TG from VLDL, and a sub-cally, the increase in the TG/CE ratio in HDL, which apr hepatic lipase. How effectively HDL functions in these proached but did not quite reach statistical significance, and believed to be the basis for it correlating inversely with the clear cut reciprocal reduction found in VLDL, in the HC elopment of coronary heart disease (17) .
patients are precisely the type of changes in core lipids to be his study, we found that the initial rate ofCE transferred expected if CET were increased.
[DL to the apo B-containing lipoproteins in whole One possible technical explanation for the differences we find in CET, is that the sulfhydryl inhibitor DTNB employed to inhibit LCAT during the CET assay may have only partially inhibited cholesterol esterification in control plasma, but completely blocked it in the HC patients. If this were the case, the accumulation of newly synthesized CE in HDL would obscure the transfer of CE that had taken place, which we estimate as the mass of CE lost from HDL. This however, does not appear to be the case, since direct measurements of LCAT activity performed serially during the assay indicate that a comparable degree of inhibition was achieved in HC and control plasma with the concentration of DTNB employed. In preliminary experiments in two HC and two control subjects, we found similar differences in CET in whole plasma employing the serine protease inhibitor E-600 to inhibit LCAT (data not shown).
Another factor possibly contributing to increased CET in the HC subjects is an enrichment oftheir acceptor lipoproteins (VLDL + LDL) with lipolytic products or free fatty acids (FFA), as Tall et al. have shown, occurs normally in the postprandial state when CET is activated (9) . FFA in HC VLDL1 could be increased de novo as a result of in vivo changes, or in vitro during our assay due to the phospholipase activity of LCAT which might not be fully inhibited by DTNB (24) . Our finding that neither FFA nor lysolecithin increased makes it unlikely that the phospholipase activity of LCAT contributed significantly to the accelerated activity we observed. Since it has not been possible in our hands to reliably measure the very small amount of FFA present in VLDL, with either GLC or colorimetric methods, a small increment in the FFA content of HC VLDLI could still enhance its CET activity in a manner similar to that shown by Sammett and Tall for the entire VLDL fraction after treatment with milk lipase (25) . This increased transfer activity of VLDL, might also result from alterations in composition that enhance its avidity for CETP (26) . Further studies are required to assess this possibility.
The FC content of VLDL relative to phospholipid has been shown to be a potent modifier ofCET activity (4) . It is therefore ofinterest that we found a directional change in the FC/lecithin ratio in HC VLDLI similar to that shown earlier by Morton to increase CET (4, 26) . This finding may provide another possible explanation for the acceleration of CET we observe in HC patient. This abnormality may contribute to the formation ofa subpopulation ofVLDL which are abnormally enriched in CE. Particles generated in this way may be potentially atherogenic because they are preferentially cleared by arterial wall macrophages (27) . These findings suggest that abnormalities in lipid transfer may accelerate atherogenesis in HC patients by adversely affecting the composition of their quantitatively normal VLDL. TC, total cholesterol. * P < 0.05; * P < 0.025; and § P < 0.001.
